Eli Lilly and Company is a large biopharmaceutical company. It lobbies on health and drug-policy issues, including Medicare and Medicaid prescription drug pricing, coverage, access, and implementation of the Inflation Reduction Act. It also pushes for strong intellectual property protections and trade rules that affect pharmaceuticals, and engages on programs like 340B that affect drug discounts and hospital purchases.
Show the dominant industry call, how mixed the client looks, and the allocation across the top labeled sectors.
Annual totals based on disclosed filing amounts.
Issue rankings are based on disclosed activity mentions, with filing amounts apportioned evenly across issues within the same filing.
The lobbying registrants handling this client, ranked by disclosed filing amounts.
Lobbyists are ranked by appearances and an equal share of each filing's reported amount.
ASKIA SURUMA
The latest disclosures for this client.
ELI LILLY AND COMPANY
Q3ELI LILLY AND COMPANY
Q2The entities named in disclosed activities are the clearest available signal for where the client is aiming attention.
These contribution items line up to this client through the same lobbying firm and reporting window, and when available the same contributing lobbyist.
ELI LILLY AND COMPANY
DAVID TALBOT
ELI LILLY AND COMPANY
JUAN MACHADO
ELI LILLY AND COMPANY
mr FRANK DE LIMA
ELI LILLY AND COMPANY
SARAH KYLE
ELI LILLY AND COMPANY
SHANNON STEHOUWER
ELI LILLY AND COMPANY
SHAWN O'NEAIL
ELI LILLY AND COMPANY
THOMAS CORDREY ROBERGE jr
ELI LILLY AND COMPANY
ELI LILLY AND COMPANY
Q1ELI LILLY AND COMPANY
Q4ELI LILLY AND COMPANY
2AELI LILLY AND COMPANY
1AELI LILLY AND COMPANY
Q3ELI LILLY AND COMPANY
2AELI LILLY AND COMPANY
1AELI LILLY AND COMPANY
Q2ELI LILLY AND COMPANY
Q1